Nothing Special   »   [go: up one dir, main page]

BR112017011982A2 - roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco. - Google Patents

roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.

Info

Publication number
BR112017011982A2
BR112017011982A2 BR112017011982A BR112017011982A BR112017011982A2 BR 112017011982 A2 BR112017011982 A2 BR 112017011982A2 BR 112017011982 A BR112017011982 A BR 112017011982A BR 112017011982 A BR112017011982 A BR 112017011982A BR 112017011982 A2 BR112017011982 A2 BR 112017011982A2
Authority
BR
Brazil
Prior art keywords
rodent
drug
cell
methods
assess
Prior art date
Application number
BR112017011982A
Other languages
English (en)
Inventor
J Murphy Andrew
Burova Elena
Venus Lai Ka-Man
Tang Yajun
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112017011982A2 publication Critical patent/BR112017011982A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

animais não humanos, métodos e composições para a produção e uso dos mesmos, são fornecidos, sendo que os ditos animais não humanos compreendem uma humanização de um gene do grupo de diferenciação 274 (cd274). tais animais não humanos podem ser descritos, em algumas modalidades, como tendo uma modificação genética em um gene cd274 endógeno de modo que os ditos animais não humanos expressam um ligante de morte celular programada 1 (pd-l1) que inclui uma porção humana e uma porção endógena (por exemplo, uma porção não humana).
BR112017011982A 2014-12-09 2015-12-09 roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco. BR112017011982A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089549P 2014-12-09 2014-12-09
US201562106525P 2015-01-22 2015-01-22
PCT/US2015/064626 WO2016094481A1 (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Publications (1)

Publication Number Publication Date
BR112017011982A2 true BR112017011982A2 (pt) 2018-01-16

Family

ID=55024286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011982A BR112017011982A2 (pt) 2014-12-09 2015-12-09 roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.

Country Status (27)

Country Link
US (4) US9913461B2 (pt)
EP (3) EP3230320B1 (pt)
JP (3) JP2018500896A (pt)
KR (2) KR102457921B1 (pt)
CN (2) CN107257624B (pt)
AU (2) AU2015360667B2 (pt)
BR (1) BR112017011982A2 (pt)
CA (1) CA2968675C (pt)
CY (1) CY1123723T1 (pt)
DK (2) DK3808775T3 (pt)
ES (2) ES2841353T3 (pt)
FI (1) FI3808775T3 (pt)
HR (2) HRP20240855T1 (pt)
HU (2) HUE067123T2 (pt)
IL (3) IL282649B (pt)
LT (2) LT3230320T (pt)
MX (1) MX2017007636A (pt)
NZ (2) NZ731954A (pt)
PL (1) PL3808775T3 (pt)
PT (2) PT3808775T (pt)
RS (2) RS65664B1 (pt)
RU (1) RU2711729C2 (pt)
SG (2) SG11201703931QA (pt)
SI (2) SI3808775T1 (pt)
SM (2) SMT202100148T1 (pt)
WO (1) WO2016094481A1 (pt)
ZA (1) ZA201703263B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017011982A2 (pt) * 2014-12-09 2018-01-16 Regeneron Pharma roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.
LT3376857T (lt) 2015-11-20 2021-06-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną
SG11201806176PA (en) 2016-02-04 2018-08-30 Regeneron Pharma Non-human animals having an engineered angptl8 gene
ES2886958T3 (es) 2016-02-29 2021-12-21 Regeneron Pharma Roedores que tienen un gen TMPRSS humanizado
EP3476865B1 (en) * 2016-06-28 2023-09-13 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Method for constructing pd-1 gene-modified humanized animal model and use thereof
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharma conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
AU2018375796B2 (en) 2017-11-30 2024-11-21 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TRKB locus
WO2019114768A1 (en) 2017-12-12 2019-06-20 Biocytogen Jiangsu Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
ES2983967T3 (es) 2018-07-16 2024-10-28 Regeneron Pharma Modelos de roedores de enfermedad DITRA y usos de estos
CN110846321B (zh) * 2018-08-21 2021-11-19 中国科学院动物研究所 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途
US20210380978A1 (en) * 2018-10-15 2021-12-09 The Brigham And Women`S Hospital, Inc. The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
CN109979539B (zh) * 2019-04-10 2020-10-02 电子科技大学 基因序列优化方法、装置及数据处理终端
CN114621971A (zh) * 2021-02-19 2022-06-14 百奥赛图(北京)医药科技股份有限公司 经遗传修饰的非人动物及其构建方法和应用
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6485964B1 (en) * 1995-03-20 2002-11-26 Arris Pharmaceutical Corporation Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
EP1297135B1 (en) 2000-06-28 2013-01-09 Genetics Institute, LLC Pd-l2 molecules: novel pd-1 ligands and uses therefor
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
HUE065675T2 (hu) * 2002-07-03 2024-06-28 Ono Pharmaceutical Co PD-L1 elleni antitesteket tartalmazó immunpotenciáló készítmények
EP1573314B1 (en) * 2002-12-16 2008-07-23 Genentech, Inc. Transgenic mice expressing human cd20
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
ES2364335T3 (es) * 2003-12-24 2011-08-31 G2 Inflammation Pty Ltd Mamífero no humano transgénico que comprende un polinucleótido que codifica el c5ar humano o humanizado.
EP1701611B1 (en) 2003-12-24 2011-05-18 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
FI3428191T3 (fi) 2004-10-06 2025-01-21 Mayo Found Medical Education & Res B7-h1 ja pd-1 munuaissolukarsinooman hoidossa
SI1802193T1 (sl) 2004-10-19 2014-08-29 Regeneron Pharmaceuticals, Inc. Postopek za generiranje miši, homozigotne za genetsko modifikacijo
EP2982379A1 (en) * 2005-07-01 2016-02-10 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007100098A1 (ja) 2006-03-03 2007-09-07 Kyoto University 細胞表面機能分子の細胞外領域多量体
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
WO2010042189A2 (en) 2008-10-08 2010-04-15 Intrexon Corporation Engineered cells expressing multiple immunomodulators and uses thereof
MX2011007660A (es) * 2008-12-18 2011-08-17 Kingdon Craig R Animales transgenicos no humanos que expresan anticuerpos humanizados y usos de los mismos.
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
SI2470671T1 (sl) * 2009-08-28 2015-04-30 Regeneron Pharmaceuticals, Inc. Antikinska protitelesa, ki se veĺ˝ejo na veäś kemokinov cc
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
WO2011060357A2 (en) 2009-11-16 2011-05-19 The Ohio State University Engineered xenogeneic cells for repair of biological tissue
SMT202000195T1 (it) * 2009-11-24 2020-05-08 Medimmune Ltd Agenti leganti direzionati contro b7-h1
EP3498730A1 (en) * 2009-12-21 2019-06-19 Regeneron Pharmaceuticals, Inc. Humanized fc gamma r mice
US8507663B2 (en) * 2010-04-06 2013-08-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
DK3375284T3 (da) 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
KR102234632B1 (ko) 2011-10-28 2021-04-02 리제너론 파아마슈티컬스, 인크. 사람화된 ｉｌ-6 및 ｉｌ-6 수용체
EP4052572A1 (en) 2011-10-28 2022-09-07 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
MY178723A (en) 2011-10-28 2020-10-20 Regeneron Pharma Genetically modified major histocompatibility complex mice
WO2013078230A1 (en) 2011-11-23 2013-05-30 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
HUE051954T2 (hu) 2011-11-28 2021-03-29 Merck Patent Gmbh ANTI-PD-L1 ellenanyagok és alkalmazásaik
EP2890715B1 (en) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
CN104755495A (zh) * 2012-08-21 2015-07-01 赛诺菲 通过施用il-4r拮抗剂治疗或预防哮喘的方法
NZ741951A (en) 2012-09-07 2020-04-24 Institute For Res In Biomedicine Irb Genetically modified non-human animals and methods of use thereof
PT2914102T (pt) 2012-11-05 2018-01-15 Univ Yale Animais não-humanos geneticamente modificados e métodos de utilização dos mesmos
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
WO2014130706A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
CN105164153B (zh) 2013-02-20 2020-04-24 瑞泽恩制药公司 人源化的t细胞共受体的小鼠
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
SI2958937T1 (sl) 2013-02-22 2018-12-31 Regeneron Pharmaceuticals, Inc. Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
DK3456831T3 (da) * 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
CN108441497B (zh) 2013-09-23 2021-10-29 瑞泽恩制药公司 具有人源化信号调节蛋白基因的非人动物
JP6505689B2 (ja) 2013-11-19 2019-04-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化ｂ細胞活性化因子遺伝子を有する非ヒト動物
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
SG11201604886WA (en) 2014-04-08 2016-07-28 Regeneron Pharma Non-human animals having humanized fc-gamma receptors
NO2785538T3 (pt) 2014-05-07 2018-08-04
EP3145307B1 (en) 2014-05-19 2019-02-06 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals expressing human epo
EP3683238A1 (en) 2014-06-19 2020-07-22 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
DK3223605T3 (da) 2014-11-24 2020-11-16 Regeneron Pharma Ikke-humane dyr, der eksprimerer humaniseret cd3-kompleks
KR102313073B1 (ko) 2014-12-05 2021-10-18 리제너론 파마슈티칼스 인코포레이티드 인간화 분화 클러스터 47 유전자를 가진 비인간 동물
BR112017011982A2 (pt) * 2014-12-09 2018-01-16 Regeneron Pharma roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.
LT3376857T (lt) 2015-11-20 2021-06-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1

Also Published As

Publication number Publication date
JP2022184973A (ja) 2022-12-13
US10881086B2 (en) 2021-01-05
WO2016094481A1 (en) 2016-06-16
ES2841353T3 (es) 2021-07-08
PT3808775T (pt) 2024-07-09
KR102457921B1 (ko) 2022-10-25
CN107257624A (zh) 2017-10-17
FI3808775T3 (fi) 2024-07-02
US20180160663A1 (en) 2018-06-14
AU2015360667A1 (en) 2017-06-08
HRP20202034T1 (hr) 2021-02-19
EP4399969A3 (en) 2024-10-30
JP7488861B2 (ja) 2024-05-22
SG10202100792XA (en) 2021-03-30
RU2017123754A3 (pt) 2019-06-24
US20240389563A1 (en) 2024-11-28
LT3808775T (lt) 2024-07-10
AU2015360667B2 (en) 2021-09-23
JP7145920B2 (ja) 2022-10-03
CA2968675A1 (en) 2016-06-16
CN107257624B (zh) 2021-07-13
US20160157469A1 (en) 2016-06-09
SMT202100148T1 (it) 2021-05-07
LT3230320T (lt) 2021-01-11
KR20210130251A (ko) 2021-10-29
US9913461B2 (en) 2018-03-13
CN113412818B (zh) 2022-11-04
EP3808775B1 (en) 2024-04-17
HUE067123T2 (hu) 2024-10-28
SMT202400313T1 (it) 2024-09-16
EP3230320A1 (en) 2017-10-18
EP3808775A1 (en) 2021-04-21
RS61218B1 (sr) 2021-01-29
PT3230320T (pt) 2021-01-08
DK3230320T3 (da) 2021-01-11
IL282649A (en) 2021-06-30
JP2018500896A (ja) 2018-01-18
HUE052606T2 (hu) 2021-05-28
ES2982515T3 (es) 2024-10-16
IL275864B (en) 2021-05-31
DK3808775T3 (da) 2024-07-01
MX2017007636A (es) 2018-03-28
CN113412818A (zh) 2021-09-21
IL275864A (en) 2020-08-31
KR20170101910A (ko) 2017-09-06
ZA201703263B (en) 2023-02-22
JP2021003130A (ja) 2021-01-14
RU2711729C2 (ru) 2020-01-21
AU2021286369A1 (en) 2022-01-20
SG11201703931QA (en) 2017-06-29
US12089575B2 (en) 2024-09-17
KR102316842B1 (ko) 2021-10-25
EP4399969A2 (en) 2024-07-17
EP3230320B1 (en) 2020-10-07
US20210105983A1 (en) 2021-04-15
CA2968675C (en) 2023-10-17
PL3808775T3 (pl) 2024-08-19
NZ731954A (en) 2024-11-29
SI3230320T1 (sl) 2021-02-26
IL252695A0 (en) 2017-08-31
RU2017123754A (ru) 2019-01-10
RS65664B1 (sr) 2024-07-31
CY1123723T1 (el) 2022-03-24
HRP20240855T1 (hr) 2024-10-11
IL282649B (en) 2022-07-01
IL252695B (en) 2020-07-30
NZ770783A (en) 2024-11-29
SI3808775T1 (sl) 2024-08-30

Similar Documents

Publication Publication Date Title
BR112017011982A2 (pt) roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.
BR112016029650A2 (pt) roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
BR112018010158A2 (pt) roedor, polipeptídeo lag-3 humanizado, célula ou tecido, célula-tronco embrionária e embrião de roedor, métodos para produzir um roedor, para avaliar a eficácia antitumoral e as propriedades farmacocinéticas de uma droga
BR112017010490A2 (pt) roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
Underwood et al. Biology and diseases of ruminants (sheep, goats, and cattle)
CL2020000345A1 (es) Mezclas agrícolas.
EA201991255A1 (ru) Регулируемая транскрипция
BR112016025745A2 (pt) roedor, camundongo, métodos para produção de um roedor e de um camundongo e para triagem de antagonista
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
PE20200496A1 (es) Virus de la enfermedad de newcastle y usos de los mismos
MX2016014504A (es) Animales c5 y c3 humanizados.
Scerbo et al. Ventx factors function as Nanog-like guardians of developmental potential in Xenopus
BR112016011004A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
AR100216A1 (es) Edición de genes multiplexados
BR112016024565A2 (pt) composições e métodos de tratar hemoglobinopatias
BR112016026245A2 (pt) ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor?
BR112016002385A2 (pt) animal não humano, célula, tecido ou embrião, vetor de alvejamento, constructo de vetor de alvejamento, e, métodos para produzir um animal não humano e para modificar um lócus de incrna em uma célula pluripotente
ZA201907822B (en) Methods for gender determination of avian embryos in unhatched eggs and means thereof
EP4069821A4 (en) SYSTEM FOR PRODUCING CULTURED MEAT, TISSUES AND RELATED PRODUCTS FROM CELLS
O’Rourke et al. Biology and diseases of amphibians
BR112017016883A2 (pt) compostos com atividade antitumoral
MX2017006491A (es) Composiciones y métodos para la modulación de la actividad at2r.
RU2016144561A (ru) Способ определения направления продуктивности мясных кур в эмбриогенезе
BR112017014616A2 (pt) imunotoxina para o uso no tratamento de leishmaniose

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]